|  |  |  |  |
| --- | --- | --- | --- |
|  | **P1** | **P2** | **P3** |
| **Reporting physician(s) (e-mail)** |  |  |  |
| **Previously reported (reference)** |  |  |  |
|  | **DEMOGRAPHICS** |
| **Age (years)** |  |  |  |
| **Gender (M/F)** |  |  |  |
| **Ethnicity** |  |  |  |
|  | **PREVIOUS CLINICAL DATA** |
| **IEI (MYD88 or IRAK-4) (mutation)** |  |  |  |
| **Previous infections** |  |  |  |
| **Comorbidities and Risk Factors (including BMI)** |  |  |  |
| **Baseline/prophylactic treatment** |  |  |  |
|  | **PREVIOUS SARS-CoV-2 VACCINATION** |
| **Vaccine****Doses****Days/months before symptoms onset** |  |  |  |
|  | **DIAGNOSIS OF SARS-CoV-2 INFECTION** |
| **Diagnostic method****(nasopharyngeal PCR, serology…)** |  |  |  |
| **Days after symptoms onset** |  |  |  |
|  | **SYMPTOMS AND SEVERITY** |
| **Hospitalization at general ward****(Y/N, length of admission)** |  |  |  |
| **ICU or SIMILAR FACILITIES admission** **(Y/N, length of admission)** |  |  |  |
| **Description of X-Ray/CT-scan imaging****(Interstitial, lobar, ground glass opacities, extension, pleural effusion, pulmonary embolism …)** |  |  |  |
| **ARDS (Y/N)****Please specify pO2/FIO2 or SpO2/FIO2 value** **At Hospital admission** **At ICU admission** **Lowest value** | **pO2/FIO2 SpO2/FIO2****pO2/FIO2 SpO2/FIO2****pO2/FIO2 SpO2/FIO2** | **pO2/FIO2 SpO2/FIO2****pO2/FIO2 SpO2/FIO2****pO2/FIO2 SpO2/FIO2** | **pO2/FIO2 SpO2/FIO2****pO2/FIO2 SpO2/FIO2****pO2/FIO2 SpO2/FIO2** |
| **Oxygen therapy (Y/N)****Please specify:** **Type** **Days since initial presentation** **Days on oxygen therapy by device** |  |  |  |
| **- Fever (days/max temperature)** **Other symptoms** **- Admission duration** **- Days since first symptoms to hospital admission****- Days from hospital admission to ICU admission** **- Contact exposure before admission (days)****- Min SpO2** |  |  |  |
| **Lymphocytes/µL** **Neutrophils/µL** **Platelets/µL** **PCT**  **ng/mL** **CRP mg/L** **Ferritin ng/mL** **D-dimer ug/L** **LDH IU/L****Bilirrubin at hospital and/or ICU admission****Creatinine at hospital and/or ICU admission** | **Lower Higher****Lower Higher** | **Lower Higher****Lower Higher** | **Lower Higher****Lower Higher** |
| **Treatment (Remdesivir, Tocilizumab, Anakinra, corticosteroids, antibiotics…)****(Please, specify days after symptoms onset)** |  |  |  |
| **WHO CPSS (see in the last page)** |  |  |  |
|  | **OTHER CONCURRENT INFECTIONS (coinfection or secondary)****Please specify whether the patient (s) had other confirmed or presumed infection (particularly bacterial infections) and whether patients were treated with antibiotics (including day after symptoms onset).** |
|  |  |  |  |
|  | **OTHER RELATIVES OR CLOSE CONTACTS INFECTED BY SARS-COV-2****Please specify (referring to the pedigree -next page), age, risk factors, and whether they were infected, and include a brief description of severity (indicating the WHO score). Indicate whether no PCR or serology test were performed to aymptomatic individuals.**  |
|  |  |  |  |

## IEI: Inborn Error of Immunity; unk.: unknown microorganism; PCT: procalcitonine; CRP: C-reactive protein; NR: normal range; BMI: body mass index; BA: before admission SpO2: oxygen saturation measured by fingertip pulse oximeter; sGC: systemic glucocorticosteroids; LMWH: low molecular weight heparin; lpm: liters per minute; max.: maximum; LDH: lactate dehydrogenase; WHO CPSS: World Health Organization Clinical Progression Scale Score

Maximum PCT, CRP, ferritin and D-dimer levels and minimum platelets, lymphocyte and neutrophils counts during the admission are shown in the table. Fever total days and maximum temperature are described in the table, as well as total admission days, symptomatic days before admission and known positive contact exposure before admission (positive SARS-CoV-2 contact is defined a person positive to specific SARS-CoV-2 DNA or antigen in oral-nasopharyngeal sample, whom the patient was exposed for 15 minutes or more, within 6 feet distance: Available at: https://www.cdc.gov/coronavirus/2019-ncov/php/public-health-recommendations.html)

**PEDIGREE** (include *MYD88* or *IRAK-4* genetics. Indicate by black symbols patients with critical COVID, with solid gray for moderate cases, and white symbols for asymptomatic or mild; indicate with an arrow the confirmed or suspected index case). Add ‘+’ and ‘-’ to indicate the presence and absence, respectively, of antibodies against SARS-CoV-2 in the serum of the individual, and ND to indicate those with no serology performed.

**Example:**

Mutation(s): *IRAK-4* p.E250X, p.P352S

?

WT/p.E408X

ND

+

P1

P3

P2

+

+

+

\_

WT/p.E408X

WT/WT

p.E408X/ p.P715S

p.E408X/ p.P715S

p.E408X/ p.P715S

WT/ p.P715S

\_

+

p.E408X/ p.P715S

ND

P4

**WHO CLINICAL PROGRESSION SCALE**



From: WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. Lancet Infect Dis. 2020 Aug;20(8):e192-e197. doi: 10.1016/S1473-3099(20)30483-7.